Press Releases

You Narrowed By: Business/Product Release

Showing 106-140 of 173

First Prev 1 2 3 4 5 Next Last

2011
November
November 1	Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent

October
October 27	Abbott's Lupron Depot-PED (leuprolide acetate for depot suspension) 1-Month Formulation Now Includes 18-Year Long-Term Data in Label
October 27	Abbott Launches Glucerna® Hunger Smart™ Nutrition Products for People with Diabetes
October 24	Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
October 22	Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select Phase 2b Trial at ECTRIMS/ACTRIMS
October 19	Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
October 4	Abbott Enrolls First U.S. Patient in Global EXCEL Trial Comparing XIENCE to Coronary Artery Bypass Surgery

September
September 29	Abbott Announces Availability of Two New CE-Marked Molecular Assays for its m2000 System to Detect Infections Spread in Healthcare Settings
September 20	Abbott Earns 100 Percent Banned Substance Free Certification for all of its EAS® Sports Nutrition Products
September 8	Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia

August
August 30	Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer
August 26	Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection
August 22	Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery
August 22	FDA Clears Abbott’s Genetic FISH Panel for Leukemia Patient Prognosis
August 16	First Patient in Japan Treated with Abbott's Bioresorbable Vascular Scaffold as Part of Global Clinical Trial
August 16	Abbott Expanding Manufacturing Capacity in China to Meet Demands of Fast-Growing Nutrition Market
August 16	Abbott Receives FDA Approval for Two Three-Month Strengths of Lupron Depot-PED® (leuprolide acetate for depot suspension) for the Treatment of Central Precocious Puberty (CPP)
August 11	Abbott’s PediaSure® Brand Aims to Help Moms With Picky Eaters "Take Back the Table" By Building Lifelong Healthy Eating Habits
August 10	Abbott Introduces Vector-borne Pathogen Test to Detect Microorganisms Carried by Ticks and Other Insects
August 10	Abbott Receives U.S. FDA Approval for RX Herculink Elite^® Renal Stent System for Treatment of Renal Artery Disease
August 9	Biogen Idec And Abbott Announce Positive Top-Line Results From The First Registrational Trial For Daclizumab HYP In Relapsing-Remitting Multiple Sclerosis

July
July 28	Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels
July 27	Abbott’s HIV Combo Test Detects Infections Earlier, Provides Valuable Information to Help Prevent Further HIV Transmission and May Save Treatment Costs

June
June 24	New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients with Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
June 21	Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
June 20	Abbott Receives FDA Approval for a New Six-Month Formulation of Lupron Depot® (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer
June 16	Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes
June 14	Abbott Receives FDA Approval For CREON® (Pancrelipase) Infant-Specific Dosage For Patients With Exocrine Pancreatic Insufficiency Due To Cystic Fibrosis
June 13	New National Survey Results Reveal Majority of Men Find it Easier to Care for Their Car Than for Their Personal Health
June 9	Abbott Reports Interim Results from Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease

May
May 26	Abbott Statement on Interim Study Results of AIM-HIGH
May 25	Abbott Receives CE Mark for its RealTime Molecular Test for Cytomegalovirus
May 24	Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels
May 23	Abbott Completes Submission of New Molecular Test Intended for Non-small-cell Lung Cancer Therapy Selection
May 20	Abbott Introduces New ZonePerfect® Sweet & Salty Nutrition Bars

First Prev 1 2 3 4 5 Next Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.